Calidi Net Current Asset Value from 2010 to 2026
| CLDI Stock | 0.82 0.01 1.20% |
Net Current Asset Value | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check Calidi Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Calidi Biotherapeutics' main balance sheet or income statement drivers, such as Tax Provision of 13.6 K, Depreciation And Amortization of 1.9 M or Interest Expense of 1.2 M, as well as many indicators such as Price To Sales Ratio of 1 K, Dividend Yield of 0.14 or PTB Ratio of 5.65. Calidi financial statements analysis is a perfect complement when working with Calidi Biotherapeutics Valuation or Volatility modules.
Calidi | Net Current Asset Value | Build AI portfolio with Calidi Stock |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Calidi Biotherapeutics Correlation against competitors. For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is there potential for Biotechnology market expansion? Will Calidi introduce new products? Factors like these will boost the valuation of Calidi Biotherapeutics. Projected growth potential of Calidi fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Calidi Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Calidi's accounting equity. The concept of intrinsic value - what Calidi Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Calidi Biotherapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Calidi Biotherapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Calidi Biotherapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Calidi Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.